The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
Twenty-seven patients with uterine fibroids were treated for 3 months with the GnRH-agonist goserelin prior to surgical myomectomy. Ovarian function was suppressed reliably in all patients. After three applications, 15 fibroids were reduced in volume by more than 50%, and one complete remission was achieved. Seven patients showed a decrease of 10-50% in volume. However, in 5 cases there was no significant reduction. Analysing the time course of the fibroid reduction, the response can be predicted in most cases as early as four weeks after the first injection. Retrospective statistical analysis showed that a 50% reduction in fibroid size due to GnRH treatment is preceded by a 35% reduction after 4 weeks in 81% of cases, and after 8 weeks in all cases. Only 2 of 12 fibroids, which showed a smaller response (less than 50%) to GnRH therapy, were reduced by more than 35% after 4 and 8 weeks. In most cases it seems to be possible to estimate the individual response to GnRH-application after the first injection, so that it is possible to stop therapy in non-responding patients.
Hackenberg
R
R
Department of Obstetrics and Gynecology, Philipps-University, Marburg, FRG.
Gesenhues
T
T
Deichert
U
U
Duda
V
V
Schmidt-Rhode
P
P
Schulz
K D
KD
D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D017273:Goserelin; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D017273:Goserelin; D004958:Estradiol; D002064:Buserelin